{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:45:35Z","timestamp":1786981535371,"version":"build-2736575974"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000969","name":"Australian Academy of Science","doi-asserted-by":"publisher","award":["2025ZNSFSC0549"],"award-info":[{"award-number":["2025ZNSFSC0549"]}],"id":[{"id":"10.13039\/501100000969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12068-3","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:21:31Z","timestamp":1780392091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nanomedicine in precision treatment of gastric cancer: current clinical landscape"],"prefix":"10.1007","volume":"53","author":[{"given":"ShengJin","family":"Tu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"issue":"1","key":"12068_CR1","doi-asserted-by":"publisher","first-page":"e70043","DOI":"10.3322\/caac.70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A (2026) Cancer statistics, 2026. CA Cancer J Clin 76(1):e70043. https:\/\/doi.org\/10.3322\/caac.70043","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"12068_CR2","doi-asserted-by":"publisher","first-page":"e70245","DOI":"10.1002\/cncr.70245","volume":"132","author":"P Danpanichkul","year":"2026","unstructured":"Danpanichkul P, Pang Y, Tothanarungroj P, Dejvajara D, Kim D, Saokhieo P et al (2026) Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries. Cancer 132(1):e70245. https:\/\/doi.org\/10.1002\/cncr.70245","journal-title":"Cancer"},{"issue":"1","key":"12068_CR3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-025-01698-y","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen Y, Jia K, Xie Y, Yuan J, Liu D, Jiang L et al (2025) The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol 18(1):42. https:\/\/doi.org\/10.1186\/s13045-025-01698-y","journal-title":"J Hematol Oncol"},{"issue":"7","key":"12068_CR4","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/jso.26834","volume":"125","author":"C Cann","year":"2022","unstructured":"Cann C, Ciombor KK (2022) Systemic therapy for gastric cancer: Perioperative strategies and beyond. J Surg Oncol 125(7):1151\u20131160. https:\/\/doi.org\/10.1002\/jso.26834","journal-title":"J Surg Oncol"},{"key":"12068_CR5","doi-asserted-by":"publisher","first-page":"1432490","DOI":"10.3389\/fphar.2024.1432490","volume":"15","author":"P Huang","year":"2024","unstructured":"Huang P, Wen F, Li Q (2024) Current concepts of the crosstalk between lncRNA and E2F1: shedding light on the cancer therapy. Front Pharmacol 15:1432490. https:\/\/doi.org\/10.3389\/fphar.2024.1432490","journal-title":"Front Pharmacol"},{"key":"12068_CR6","doi-asserted-by":"publisher","unstructured":"Japanese gastric cancer treatment guidelines (2026) (7th edition). Gastric Cancer https:\/\/doi.org\/10.1007\/s10120-025-01698-4","DOI":"10.1007\/s10120-025-01698-4"},{"issue":"4","key":"12068_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3748\/wjg.v30.i4.286","volume":"30","author":"G Christodoulidis","year":"2024","unstructured":"Christodoulidis G, Koumarelas KE, Kouliou MN (2024) Revolutionizing gastric cancer treatment: The potential of immunotherapy. World J Gastroenterol 30(4):286\u2013289. https:\/\/doi.org\/10.3748\/wjg.v30.i4.286","journal-title":"World J Gastroenterol"},{"key":"12068_CR8","doi-asserted-by":"publisher","first-page":"1129680","DOI":"10.3389\/fonc.2023.1129680","volume":"13","author":"H Zeng","year":"2023","unstructured":"Zeng H, Zhang M, Xie Y, Wang M, Dai J, Zhu X et al (2023) Primary renal mucinous adenocarcinoma masquerading as a giant renal cyst: a case report. Front Oncol 13:1129680. https:\/\/doi.org\/10.3389\/fonc.2023.1129680","journal-title":"Front Oncol"},{"issue":"1","key":"12068_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","volume":"24","author":"M Zhang","year":"2025","unstructured":"Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N et al (2025) Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol Cancer 24(1):136. https:\/\/doi.org\/10.1186\/s12943-025-02305-x","journal-title":"Mol Cancer"},{"issue":"16","key":"12068_CR10","doi-asserted-by":"publisher","first-page":"e70094","DOI":"10.1002\/cam4.70094","volume":"13","author":"F Wen","year":"2024","unstructured":"Wen F, Huang P, Wu Q, Yang Y, Zhou K, Zhang M et al (2024) Promising first-line immuno-combination therapies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis. Cancer Med 13(16):e70094. https:\/\/doi.org\/10.1002\/cam4.70094","journal-title":"Cancer Med"},{"issue":"7","key":"12068_CR11","doi-asserted-by":"publisher","first-page":"e70017","DOI":"10.1002\/eji.70017","volume":"55","author":"Y Lv","year":"2025","unstructured":"Lv Y, Ma G (2025) Platelet-Based Nanotechnology Improves Cancer Immunotherapy. Eur J Immunol 55(7):e70017. https:\/\/doi.org\/10.1002\/eji.70017","journal-title":"Eur J Immunol"},{"issue":"4","key":"12068_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12032-025-02650-3","volume":"42","author":"T Liu","year":"2025","unstructured":"Liu T, Gu Y, Zhao Y, Li Y (2025) Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention. Med Oncol 42(4):93. https:\/\/doi.org\/10.1007\/s12032-025-02650-3","journal-title":"Med Oncol"},{"issue":"5","key":"12068_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"DJ Irvine","year":"2020","unstructured":"Irvine DJ, Dane EL (2020) Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol 20(5):321\u2013334. https:\/\/doi.org\/10.1038\/s41577-019-0269-6","journal-title":"Nat Rev Immunol"},{"issue":"37","key":"12068_CR14","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.3748\/wjg.v28.i37.5403","volume":"28","author":"YN Ding","year":"2022","unstructured":"Ding YN, Xue M, Tang QS, Wang LJ, Ding HY, Li H et al (2022) Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges. World J Gastroenterol 28(37):5403\u20135419. https:\/\/doi.org\/10.3748\/wjg.v28.i37.5403","journal-title":"World J Gastroenterol"},{"issue":"4","key":"12068_CR15","doi-asserted-by":"publisher","first-page":"e70006","DOI":"10.1002\/btm2.70006","volume":"10","author":"J Lopes","year":"2025","unstructured":"Lopes J, Lopes D, Motallebi M, Ye M, Xue Y, Vieira ACF et al (2025) Biomembrane-coated nanosystems as next-generation delivery systems for the treatment of gastrointestinal cancers. Bioeng Transl Med 10(4):e70006. https:\/\/doi.org\/10.1002\/btm2.70006","journal-title":"Bioeng Transl Med"},{"issue":"1","key":"12068_CR16","doi-asserted-by":"publisher","first-page":"tfag015","DOI":"10.1093\/toxres\/tfag015","volume":"15","author":"W Lou","year":"2026","unstructured":"Lou W, Ren W, Huang S, Chen B (2026) A multi-omics study unravels the mechanism of water pollutants in gastric cancer: integrating network toxicology, machine learning, and tumor microenvironment remodeling. Toxicol Res (Camb) 15(1):tfag015. https:\/\/doi.org\/10.1093\/toxres\/tfag015","journal-title":"Toxicol Res (Camb)"},{"key":"12068_CR17","doi-asserted-by":"publisher","unstructured":"And\u00f3n FT, Rosales S\u00e1nchez A, Pensado-L\u00f3pez A, Garc\u00eda-Campelo R, Takimoto CH (2026) Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment. J Immunother Cancer 14(2). https:\/\/doi.org\/10.1136\/jitc-2025-014457","DOI":"10.1136\/jitc-2025-014457"},{"key":"12068_CR18","doi-asserted-by":"publisher","first-page":"106978","DOI":"10.1016\/j.jsbmb.2026.106978","volume":"259","author":"K Kaliyamoorthi","year":"2026","unstructured":"Kaliyamoorthi K (2026) Steroid-induced modulation of the tumor immune microenvironment: Implications for cancer progression and immunotherapy outcomes. J Steroid Biochem Mol Biol 259:106978. https:\/\/doi.org\/10.1016\/j.jsbmb.2026.106978","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"6","key":"12068_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis K, Christofides A, Shah R, Yeo YY, Jiang S, Charest A et al (2025) The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat Cancer 6(6):924\u2013937. https:\/\/doi.org\/10.1038\/s43018-025-00986-3","journal-title":"Nat Cancer"},{"key":"12068_CR20","doi-asserted-by":"publisher","first-page":"1353787","DOI":"10.3389\/fimmu.2024.1353787","volume":"15","author":"A Nicolini","year":"2024","unstructured":"Nicolini A, Ferrari P (2024) Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy. Front Immunol 15:1353787. https:\/\/doi.org\/10.3389\/fimmu.2024.1353787","journal-title":"Front Immunol"},{"issue":"1","key":"12068_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/s12967-022-03792-y","volume":"20","author":"Y Chen","year":"2022","unstructured":"Chen Y, Yin J, Zhao L, Zhou G, Dong S, Zhang Y et al (2022) Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing. J Transl Med 20(1):563. https:\/\/doi.org\/10.1186\/s12967-022-03792-y","journal-title":"J Transl Med"},{"key":"12068_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.matbio.2024.06.004","volume":"132","author":"P Li","year":"2024","unstructured":"Li P, Zhang H, Chen T, Zhou Y, Yang J, Zhou J (2024) Cancer-associated fibroblasts promote proliferation, angiogenesis, metastasis and immunosuppression in gastric cancer. Matrix Biol 132:59\u201371. https:\/\/doi.org\/10.1016\/j.matbio.2024.06.004","journal-title":"Matrix Biol"},{"issue":"2","key":"12068_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.32604\/or.2024.052207","volume":"33","author":"M Santos","year":"2025","unstructured":"Santos M, Martins D, Mendes F (2025) Immunotherapy in gastric cancer-A systematic review. Oncol Res 33(2):263\u2013281. https:\/\/doi.org\/10.32604\/or.2024.052207","journal-title":"Oncol Res"},{"key":"12068_CR24","doi-asserted-by":"publisher","first-page":"1639823","DOI":"10.3389\/fimmu.2025.1639823","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, Chen W, Xu T, Li J, Yu J, He Y et al (2025) The impact of aberrant lipid metabolism on the immune microenvironment of gastric cancer: a mini review. Front Immunol 16:1639823. https:\/\/doi.org\/10.3389\/fimmu.2025.1639823","journal-title":"Front Immunol"},{"issue":"5","key":"12068_CR25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/15548627.2020.1752548","volume":"17","author":"L Devis-Jauregui","year":"2021","unstructured":"Devis-Jauregui L, Eritja N, Davis ML, Matias-Guiu X, Llobet-Nav\u00e0s D (2021) Autophagy in the physiological endometrium and cancer. Autophagy 17(5):1077\u20131095. https:\/\/doi.org\/10.1080\/15548627.2020.1752548","journal-title":"Autophagy"},{"issue":"11","key":"12068_CR26","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1039\/d5na00321k","volume":"7","author":"Z Li","year":"2025","unstructured":"Li Z, Lu Y, Wang L, Shi L, Wang T (2025) Reactive oxygen species-dependent nanomedicine therapeutic modalities for gastric cancer. Nanoscale Adv 7(11):3210\u20133227. https:\/\/doi.org\/10.1039\/d5na00321k","journal-title":"Nanoscale Adv"},{"key":"12068_CR27","doi-asserted-by":"publisher","first-page":"104197","DOI":"10.1016\/j.critrevonc.2023.104197","volume":"198","author":"G Wang","year":"2024","unstructured":"Wang G, Huang Y, Zhou L, Yang H, Lin H, Zhou S et al (2024) Immunotherapy and targeted therapy as first-line treatment for advanced gastric cancer. Crit Rev Oncol Hematol 198:104197. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104197","journal-title":"Crit Rev Oncol Hematol"},{"issue":"22","key":"12068_CR28","doi-asserted-by":"publisher","first-page":"e2301770","DOI":"10.1002\/adma.202301770","volume":"36","author":"F Li","year":"2024","unstructured":"Li F, Ouyang J, Chen Z, Zhou Z, Milon Essola J, Ali B et al (2024) Nanomedicine for T-Cell Mediated Immunotherapy. Adv Mater 36(22):e2301770. https:\/\/doi.org\/10.1002\/adma.202301770","journal-title":"Adv Mater"},{"issue":"12","key":"12068_CR29","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1021\/acs.accounts.0c00518","volume":"53","author":"H Cabral","year":"2020","unstructured":"Cabral H, Kinoh H, Kataoka K (2020) Tumor-Targeted Nanomedicine for Immunotherapy. Acc Chem Res 53(12):2765\u20132776. https:\/\/doi.org\/10.1021\/acs.accounts.0c00518","journal-title":"Acc Chem Res"},{"key":"12068_CR30","doi-asserted-by":"publisher","first-page":"1699202","DOI":"10.3389\/fimmu.2026.1699202","volume":"17","author":"J Xia","year":"2026","unstructured":"Xia J, Zhai B (2026) Metabolic reprogramming orchestrates an immunosuppressive microenvironment in anaplastic thyroid cancer: mechanisms and clinical perspectives. Front Immunol 17:1699202. https:\/\/doi.org\/10.3389\/fimmu.2026.1699202","journal-title":"Front Immunol"},{"issue":"9","key":"12068_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2174\/1568009622666220413083534","volume":"22","author":"A Romo-Perez","year":"2022","unstructured":"Romo-Perez A, Dominguez-Gomez G, Chavez-Blanco A, Taja-Chayeb L, Gonzalez-Fierro A, Diaz-Romero C et al (2022) Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications. Curr Cancer Drug Targets 22(9):703\u2013716. https:\/\/doi.org\/10.2174\/1568009622666220413083534","journal-title":"Curr Cancer Drug Targets"},{"key":"12068_CR32","doi-asserted-by":"publisher","first-page":"116030","DOI":"10.1016\/j.biopha.2023.116030","volume":"170","author":"Z Shang","year":"2024","unstructured":"Shang Z, Ma Z, Wu E, Chen X, Tuo B, Li T et al (2024) Effect of metabolic reprogramming on the immune microenvironment in gastric cancer. Biomed Pharmacother 170:116030. https:\/\/doi.org\/10.1016\/j.biopha.2023.116030","journal-title":"Biomed Pharmacother"},{"key":"12068_CR33","doi-asserted-by":"publisher","unstructured":"Raoul P, De Gaetano V, Sciaraffia G, Ormea G, Cintoni M, Pozzo C et al (2024) Gastric Cancer, Immunotherapy, and Nutrition: The Role of Microbiota. Pathogens 13(5). https:\/\/doi.org\/10.3390\/pathogens13050357","DOI":"10.3390\/pathogens13050357"},{"issue":"10","key":"12068_CR34","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1158\/0008-5472.Can-24-2580","volume":"85","author":"T Zhang","year":"2025","unstructured":"Zhang T, Li Y, Zhai E, Zhao R, Qian Y, Huang Z et al (2025) Intratumoral Fusobacterium nucleatum Recruits Tumor-Associated Neutrophils to Promote Gastric Cancer Progression and Immune Evasion. Cancer Res 85(10):1819\u20131841. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-2580","journal-title":"Cancer Res"},{"key":"12068_CR35","doi-asserted-by":"publisher","unstructured":"Lo YL, Wang TY, Chen CJ, Chang YH, Lin AM (2022) Two-in-One Nanoparticle Formulation to Deliver a Tyrosine Kinase Inhibitor and microRNA for Targeting Metabolic Reprogramming and Mitochondrial Dysfunction in Gastric Cancer. Pharmaceutics 14(9). https:\/\/doi.org\/10.3390\/pharmaceutics14091759","DOI":"10.3390\/pharmaceutics14091759"},{"key":"12068_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.06.008","author":"M Zhu","year":"2025","unstructured":"Zhu M, Wang Z, He Y, Zhang B, Wu L, Liu C et al (2025) Acidic tumor microenvironment-modulated nanoparticle potentiates gastric cancer photoimmunotherapy. J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2025.06.008","journal-title":"J Adv Res"},{"key":"12068_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.msec.2017.05.128","volume":"80","author":"R Dhivya","year":"2017","unstructured":"Dhivya R, Ranjani J, Bowen PK, Rajendhran J, Mayandi J, Annaraj J (2017) Biocompatible curcumin loaded PMMA-PEG\/ZnO nanocomposite induce apoptosis and cytotoxicity in human gastric cancer cells. Mater Sci Eng C Mater Biol Appl 80:59\u201368. https:\/\/doi.org\/10.1016\/j.msec.2017.05.128","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"12068_CR38","doi-asserted-by":"publisher","unstructured":"Ajnai G, Cheng CC, Kan TC, Lu JW, Rahayu S, Chiu A et al (2022) Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers. Pharmaceutics 14(4). https:\/\/doi.org\/10.3390\/pharmaceutics14040847","DOI":"10.3390\/pharmaceutics14040847"},{"issue":"3","key":"12068_CR39","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.7150\/ijbs.125584","volume":"22","author":"K X","year":"2026","unstructured":"X K, Ali W, Chong Y, Wang Z, Xue L, Wang F (2026) Light as a Weapon: Redefining Cancer Care with Photodynamic Therapy. Int J Biol Sci 22(3):1560\u20131588. https:\/\/doi.org\/10.7150\/ijbs.125584","journal-title":"Int J Biol Sci"},{"key":"12068_CR40","doi-asserted-by":"publisher","unstructured":"Nkune NW, Abrahamse H (2023) Anti-Hypoxia Nanoplatforms for Enhanced Photosensitizer Uptake and Photodynamic Therapy Effects in Cancer Cells. Int J Mol Sci 24(3). https:\/\/doi.org\/10.3390\/ijms24032656","DOI":"10.3390\/ijms24032656"},{"issue":"10","key":"12068_CR41","doi-asserted-by":"publisher","first-page":"e2305174","DOI":"10.1002\/smll.202305174","volume":"20","author":"Z Li","year":"2024","unstructured":"Li Z, Li X, Lu Y, Zhu X, Zheng W, Chen K et al (2024) Improved Photodynamic Therapy Based on Glutaminase Blockage via Tumor Membrane Coated CB-839\/IR-780 Nanoparticles. Small 20(10):e2305174. https:\/\/doi.org\/10.1002\/smll.202305174","journal-title":"Small"},{"issue":"14","key":"12068_CR42","doi-asserted-by":"publisher","first-page":"9920","DOI":"10.1039\/d4ra00497c","volume":"14","author":"J Situ","year":"2024","unstructured":"Situ J, Yang Y, Zhang L, Yan H, Cheng Y (2024) Integration of O(2)-economised tumour-targeted photosensitive magnetic nanomaterials in the diagnosis and therapy of gastric cancer. RSC Adv 14(14):9920\u20139932. https:\/\/doi.org\/10.1039\/d4ra00497c","journal-title":"RSC Adv"},{"issue":"8","key":"12068_CR43","doi-asserted-by":"publisher","first-page":"102242","DOI":"10.1016\/j.xcrm.2025.102242","volume":"6","author":"S Sang","year":"2025","unstructured":"Sang S, Sun Z, Zheng W, Wang W, Islam MT, Chen Y et al (2025) TME-guided deep learning predicts chemotherapy and immunotherapy response in gastric cancer with attention-enhanced residual Swin Transformer. Cell Rep Med 6(8):102242. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102242","journal-title":"Cell Rep Med"},{"key":"12068_CR44","doi-asserted-by":"publisher","first-page":"116317","DOI":"10.1016\/j.biopha.2024.116317","volume":"172","author":"B Wang","year":"2024","unstructured":"Wang B, Song B, Li Y, Zhao Q, Tan B (2024) Mapping spatial heterogeneity in gastric cancer microenvironment. Biomed Pharmacother 172:116317. https:\/\/doi.org\/10.1016\/j.biopha.2024.116317","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"12068_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-025-02328-4","volume":"24","author":"L Kan","year":"2025","unstructured":"Kan L, Yu Y, Wang Y, Shi L, Fan T, Chen H et al (2025) The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates. Mol Cancer 24(1):125. https:\/\/doi.org\/10.1186\/s12943-025-02328-4","journal-title":"Mol Cancer"},{"issue":"5","key":"12068_CR46","doi-asserted-by":"publisher","first-page":"757","DOI":"10.4251\/wjgo.v15.i5.757","volume":"15","author":"Q Lin","year":"2023","unstructured":"Lin Q, Guan SW, Yu HB (2023) Immuno-oncology-microbiome axis of gastrointestinal malignancy. World J Gastrointest Oncol 15(5):757\u2013775. https:\/\/doi.org\/10.4251\/wjgo.v15.i5.757","journal-title":"World J Gastrointest Oncol"},{"key":"12068_CR47","doi-asserted-by":"publisher","first-page":"954992","DOI":"10.3389\/fimmu.2022.954992","volume":"13","author":"MT Bilotta","year":"2022","unstructured":"Bilotta MT, Antignani A, Fitzgerald DJ (2022) Managing the TME to improve the efficacy of cancer therapy. Front Immunol 13:954992. https:\/\/doi.org\/10.3389\/fimmu.2022.954992","journal-title":"Front Immunol"},{"issue":"14","key":"12068_CR48","doi-asserted-by":"publisher","first-page":"16676","DOI":"10.1021\/acsomega.4c00658","volume":"9","author":"B Sun","year":"2024","unstructured":"Sun B, Zheng X, Zhang X, Zhang H, Jiang Y (2024) Oxaliplatin-Loaded Mil-100(Fe) for Chemotherapy-Ferroptosis Combined Therapy for Gastric Cancer. ACS Omega 9(14):16676\u201316686. https:\/\/doi.org\/10.1021\/acsomega.4c00658","journal-title":"ACS Omega"},{"key":"12068_CR49","doi-asserted-by":"publisher","first-page":"120432","DOI":"10.1016\/j.biomaterials.2020.120432","volume":"266","author":"C Liang","year":"2021","unstructured":"Liang C, Bai X, Qi C, Sun Q, Han X, Lan T et al (2021) \u03a0 electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. Biomaterials 266:120432. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.120432","journal-title":"Biomaterials"},{"key":"12068_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00894-9","author":"C Lu","year":"2026","unstructured":"Lu C, Wang W, Fu YX (2026) Opportunities and challenges of targeting cGAS-STING in cancer. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/s41568-025-00894-9","journal-title":"Nat Rev Cancer"},{"key":"12068_CR51","doi-asserted-by":"publisher","first-page":"102790","DOI":"10.1016\/j.mtbio.2026.102790","volume":"37","author":"H Xu","year":"2026","unstructured":"Xu H, Jiang Y, Zhang R, Wang D, Feng J, Zhang H (2026) Multiple-pathway cGAS-STING activation with enhanced mild photothermal therapy through glycolysis regulation for boosting gastric cancer immunotherapy. Mater Today Bio 37:102790. https:\/\/doi.org\/10.1016\/j.mtbio.2026.102790","journal-title":"Mater Today Bio"},{"key":"12068_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000003944","author":"X Yu","year":"2025","unstructured":"Yu X, Wang L, Zhu L (2025) Intraperitoneal metastasis of gastric cancer: new insights on resident macrophages. Int J Surg. https:\/\/doi.org\/10.1097\/js9.0000000000003944","journal-title":"Int J Surg"},{"key":"12068_CR53","doi-asserted-by":"publisher","unstructured":"She Y, Cui J, Ye J, Pan F, Liang W, He X et al Nanomotor-driven precision therapy for peritoneal metastasis. Biomaterials 2025, 322:123354. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123354","DOI":"10.1016\/j.biomaterials.2025.123354"},{"issue":"15","key":"12068_CR54","doi-asserted-by":"publisher","first-page":"e2308915","DOI":"10.1002\/adma.202308915","volume":"36","author":"J Wang","year":"2024","unstructured":"Wang J, Zhao W, Zhang Z, Liu X, Xie T, Wang L et al (2024) A Journey of Challenges and Victories: A Bibliometric Worldview of Nanomedicine since the 21st Century. Adv Mater 36(15):e2308915. https:\/\/doi.org\/10.1002\/adma.202308915","journal-title":"Adv Mater"},{"issue":"12","key":"12068_CR55","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nchembio840","volume":"2","author":"I Collins","year":"2006","unstructured":"Collins I, Workman P (2006) New approaches to molecular cancer therapeutics. Nat Chem Biol 2(12):689\u2013700. https:\/\/doi.org\/10.1038\/nchembio840","journal-title":"Nat Chem Biol"},{"issue":"56","key":"12068_CR56","doi-asserted-by":"publisher","first-page":"35392","DOI":"10.1039\/d1ra01947c","volume":"11","author":"X Li","year":"2021","unstructured":"Li X, Ai S, Lu X, Liu S, Guan W (2021) Nanotechnology-based strategies for gastric cancer imaging and treatment. RSC Adv 11(56):35392\u201335407. https:\/\/doi.org\/10.1039\/d1ra01947c","journal-title":"RSC Adv"},{"issue":"2","key":"12068_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/s0046-8177(74)80061-4","volume":"5","author":"HJ Hansen","year":"1974","unstructured":"Hansen HJ, Snyder JJ, Miller E, Vandevoorde JP, Miller ON, Hines LR et al (1974) Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 5(2):139\u2013147. https:\/\/doi.org\/10.1016\/s0046-8177(74)80061-4","journal-title":"Hum Pathol"},{"issue":"10","key":"12068_CR58","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1364\/boe.574376","volume":"16","author":"AH Qatamin","year":"2025","unstructured":"Qatamin AH, Alnaanah SA, Nunn BM, O\u2019Toole MG, Mendes SB (2025) Electrochemical plasmonic sensing strategy for sensitive detection of gram-negative endotoxin in blood samples. Biomed Opt Express 16(10):4118\u20134128. https:\/\/doi.org\/10.1364\/boe.574376","journal-title":"Biomed Opt Express"},{"key":"12068_CR59","doi-asserted-by":"publisher","unstructured":"Shan CW, Chen Z, Han GC, Feng XZ, Kraatz HB Electrochemical immuno-biosensors for the detection of the tumor marker alpha-fetoprotein: A review. Talanta 2024, 271:125638. https:\/\/doi.org\/10.1016\/j.talanta.2024.125638","DOI":"10.1016\/j.talanta.2024.125638"},{"key":"12068_CR60","doi-asserted-by":"publisher","first-page":"111580","DOI":"10.1016\/j.bios.2019.111580","volume":"142","author":"E Ma","year":"2019","unstructured":"Ma E, Wang P, Yang Q, Yu H, Pei F, Li Y et al (2019) Electrochemical immunosensor based on MoS(2) NFs\/Au@AgPt YNCs as signal amplification label for sensitive detection of CEA. Biosens Bioelectron 142:111580. https:\/\/doi.org\/10.1016\/j.bios.2019.111580","journal-title":"Biosens Bioelectron"},{"key":"12068_CR61","doi-asserted-by":"publisher","first-page":"111842","DOI":"10.1016\/j.bios.2019.111842","volume":"149","author":"Y Jia","year":"2020","unstructured":"Jia Y, Li Y, Zhang S, Wang P, Liu Q, Dong Y (2020) Mulberry-like Au@PtPd porous nanorods composites as signal amplifiers for sensitive detection of CEA. Biosens Bioelectron 149:111842. https:\/\/doi.org\/10.1016\/j.bios.2019.111842","journal-title":"Biosens Bioelectron"},{"issue":"6","key":"12068_CR62","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s00604-023-05789-w","volume":"190","author":"R Ouyang","year":"2023","unstructured":"Ouyang R, Zhang W, Liu J, Li Y, Zhang J, Jiang L et al (2023) Pt Nanodot Inlaid Mesoporous NaBiOF Nanoblackberry for Remarkable Signal Amplification Toward Biomarker Detection. Mikrochim Acta 190(6):214. https:\/\/doi.org\/10.1007\/s00604-023-05789-w","journal-title":"Mikrochim Acta"},{"key":"12068_CR63","doi-asserted-by":"publisher","first-page":"114725","DOI":"10.1016\/j.jpba.2022.114725","volume":"214","author":"DC Gheorghe","year":"2022","unstructured":"Gheorghe DC, Ilie-Mihai RM, Stefan-van Staden RI, Lungu-Moscalu A, van Staden JKF (2022) Fast screening method for early diagnostic of gastric cancer based on utilization of a chitosan - S-doped graphene - based needle stochastic sensors. J Pharm Biomed Anal 214:114725. https:\/\/doi.org\/10.1016\/j.jpba.2022.114725","journal-title":"J Pharm Biomed Anal"},{"key":"12068_CR64","doi-asserted-by":"publisher","first-page":"115847","DOI":"10.1016\/j.bios.2023.115847","volume":"245","author":"P Wang","year":"2024","unstructured":"Wang P, Liang Z, Li Z, Wang D, Ma Q (2024) Plasmonic nanocavity-modulated electrochemiluminescence sensor for gastric cancer exosomal miRNA detection. Biosens Bioelectron 245:115847. https:\/\/doi.org\/10.1016\/j.bios.2023.115847","journal-title":"Biosens Bioelectron"},{"key":"12068_CR65","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bios.2018.03.022","volume":"109","author":"M Daneshpour","year":"2018","unstructured":"Daneshpour M, Karimi B, Omidfar K (2018) Simultaneous detection of gastric cancer-involved miR-106a and let-7a through a dual-signal-marked electrochemical nanobiosensor. Biosens Bioelectron 109:197\u2013205. https:\/\/doi.org\/10.1016\/j.bios.2018.03.022","journal-title":"Biosens Bioelectron"},{"key":"12068_CR66","doi-asserted-by":"publisher","first-page":"342704","DOI":"10.1016\/j.aca.2024.342704","volume":"1311","author":"H Zhu","year":"2024","unstructured":"Zhu H, Chen S, Lan F, Li W, Ji T, Zhang L et al (2024) Sensitive electrochemical biosensor for rapid detection of sEV-miRNA based turbo-like localized catalytic hairpin assembly. Anal Chim Acta 1311:342704. https:\/\/doi.org\/10.1016\/j.aca.2024.342704","journal-title":"Anal Chim Acta"},{"key":"12068_CR67","doi-asserted-by":"publisher","unstructured":"Zhuang J, Wan H, Zhang X Electrochemical detection of miRNA-100 in the sera of gastric cancer patients based on DSN-assisted amplification. Talanta 2021, 225:121981. https:\/\/doi.org\/10.1016\/j.talanta.2020.121981","DOI":"10.1016\/j.talanta.2020.121981"},{"issue":"9","key":"12068_CR68","doi-asserted-by":"publisher","first-page":"095501","DOI":"10.1088\/1361-6528\/ab55b7","volume":"31","author":"J Cai","year":"2020","unstructured":"Cai J, Ding L, Gong P, Huang J (2020) A colorimetric detection of microRNA-148a in gastric cancer by gold nanoparticle-RNA conjugates. Nanotechnology 31(9):095501. https:\/\/doi.org\/10.1088\/1361-6528\/ab55b7","journal-title":"Nanotechnology"},{"key":"12068_CR69","doi-asserted-by":"publisher","unstructured":"G\u00f3mez Gim\u00e9nez I, Rubio Garcia JJ, Carbonell Morote S, Ramia \u00c1ngel JM (2026) AI in the diagnosis and management of gastric adenocarcinoma: A systematic review. Cir Esp (Engl Ed) 800276. https:\/\/doi.org\/10.1016\/j.cireng.2026.800276","DOI":"10.1016\/j.cireng.2026.800276"},{"issue":"38","key":"12068_CR70","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1039\/c3tb20784f","volume":"1","author":"C Zhang","year":"2013","unstructured":"Zhang C, Zhou Z, Qian Q, Gao G, Li C, Feng L et al (2013) Glutathione-capped fluorescent gold nanoclusters for dual-modal fluorescence\/X-ray computed tomography imaging. J Mater Chem B 1(38):5045\u20135053. https:\/\/doi.org\/10.1039\/c3tb20784f","journal-title":"J Mater Chem B"},{"key":"12068_CR71","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.actbio.2018.03.035","volume":"72","author":"H Shi","year":"2018","unstructured":"Shi H, Yan R, Wu L, Sun Y, Liu S, Zhou Z et al (2018) Tumor-targeting CuS nanoparticles for multimodal imaging and guided photothermal therapy of lymph node metastasis. Acta Biomater 72:256\u2013265. https:\/\/doi.org\/10.1016\/j.actbio.2018.03.035","journal-title":"Acta Biomater"},{"issue":"3","key":"12068_CR72","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10120-013-0316-0","volume":"17","author":"A Ito","year":"2014","unstructured":"Ito A, Ito Y, Matsushima S, Tsuchida D, Ogasawara M, Hasegawa J et al (2014) New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice. Gastric Cancer 17(3):497\u2013507. https:\/\/doi.org\/10.1007\/s10120-013-0316-0","journal-title":"Gastric Cancer"},{"issue":"4","key":"12068_CR73","doi-asserted-by":"publisher","first-page":"e2203918","DOI":"10.1002\/advs.202203918","volume":"10","author":"Q Luo","year":"2023","unstructured":"Luo Q, Fan C, Ying W, Peng X, Hu Y, Luan Z et al (2023) In Vivo Anchoring Bis-Pyrene Probe for Molecular Imaging of Early Gastric Cancer by Endoscopic Techniques. Adv Sci (Weinh) 10(4):e2203918. https:\/\/doi.org\/10.1002\/advs.202203918","journal-title":"Adv Sci (Weinh)"},{"key":"12068_CR74","doi-asserted-by":"publisher","first-page":"3687700","DOI":"10.1155\/2021\/3687700","volume":"2021","author":"J Sharifi-Rad","year":"2021","unstructured":"Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G et al (2021) Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. Oxid Med Cell Longev 2021:3687700. https:\/\/doi.org\/10.1155\/2021\/3687700","journal-title":"Oxid Med Cell Longev"},{"issue":"3","key":"12068_CR75","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley DA (2013) nab-Paclitaxel mechanisms of action and delivery. J Control Release 170(3):365\u2013372. https:\/\/doi.org\/10.1016\/j.jconrel.2013.05.041","journal-title":"J Control Release"},{"key":"12068_CR76","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.04.021","volume":"139","author":"X Guo","year":"2019","unstructured":"Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R et al (2019) Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol 139:16\u201323. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.04.021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"12068_CR77","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/oncolo\/oyae236","volume":"29","author":"MS Dreyer","year":"2024","unstructured":"Dreyer MS, Mulcahy M, Kocherginsky M, Chen Y, Hochster HS, Kasi PM et al (2024) A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial. Oncologist 29(12):1044\u20131050. https:\/\/doi.org\/10.1093\/oncolo\/oyae236","journal-title":"Oncologist"},{"issue":"11","key":"12068_CR78","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/s1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224\u20131235. https:\/\/doi.org\/10.1016\/s1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"issue":"2","key":"12068_CR79","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10637-019-00822-3","volume":"38","author":"M Ishikawa","year":"2020","unstructured":"Ishikawa M, Iwasa S, Nagashima K, Aoki M, Imazeki H, Hirano H et al (2020) Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis. Invest New Drugs 38(2):533\u2013540. https:\/\/doi.org\/10.1007\/s10637-019-00822-3","journal-title":"Invest New Drugs"},{"issue":"1","key":"12068_CR80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/cac2.12516","volume":"44","author":"FH Wang","year":"2024","unstructured":"Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF et al (2024) The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond) 44(1):127\u2013172. https:\/\/doi.org\/10.1002\/cac2.12516","journal-title":"Cancer Commun (Lond)"},{"key":"12068_CR81","unstructured":"Phase 1 Trial of Nab-Paclitaxel PIPAC (2024) (Pressurized Intraperitoneal Aerosolized Chemotherapy) Given in Combination With Second-Line Therapy for Gastric Cancer With Peritoneal Metastases. In. Edited by National Cancer I"},{"key":"12068_CR82","unstructured":"Genotype-Guided A (2015) Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies. In. Edited by National Cancer I"},{"key":"12068_CR83","unstructured":"Phase Ib\/IIa (2011) Two-stage Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients. In"},{"key":"12068_CR84","doi-asserted-by":"publisher","first-page":"898563","DOI":"10.3389\/fonc.2022.898563","volume":"12","author":"M Zeng","year":"2022","unstructured":"Zeng M, Pi C, Li K, Sheng L, Zuo Y, Yuan J et al (2022) Patient-Derived Xenograft: A More Standard Avatar Model in Preclinical Studies of Gastric Cancer. Front Oncol 12:898563. https:\/\/doi.org\/10.3389\/fonc.2022.898563","journal-title":"Front Oncol"},{"key":"12068_CR85","doi-asserted-by":"publisher","first-page":"114751","DOI":"10.1016\/j.biopha.2023.114751","volume":"163","author":"M Zu","year":"2023","unstructured":"Zu M, Hao X, Ning J, Zhou X, Gong Y, Lang Y et al (2023) Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. Biomed Pharmacother 163:114751. https:\/\/doi.org\/10.1016\/j.biopha.2023.114751","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"12068_CR86","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12967-022-03405-8","volume":"20","author":"S Abdolahi","year":"2022","unstructured":"Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Asadzadeh Aghdaei H, Baghaei K (2022) Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med 20(1):206. https:\/\/doi.org\/10.1186\/s12967-022-03405-8","journal-title":"J Transl Med"},{"issue":"8","key":"12068_CR87","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrc3972","volume":"15","author":"RM Hoffman","year":"2015","unstructured":"Hoffman RM (2015) Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 15(8):451\u2013452. https:\/\/doi.org\/10.1038\/nrc3972","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"12068_CR88","doi-asserted-by":"publisher","first-page":"7086","DOI":"10.1039\/d5na00390c","volume":"7","author":"J Bhatt","year":"2025","unstructured":"Bhatt J, Jain S, Gupta S, Bhatia DD (2025) Nanomedicine revolutionizing cancer immunotherapy: recent advancements in nanotechnological strategies and applications. Nanoscale Adv 7(22):7086\u20137108. https:\/\/doi.org\/10.1039\/d5na00390c","journal-title":"Nanoscale Adv"},{"key":"12068_CR89","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ijbiomac.2020.12.108","volume":"169","author":"T Kopac","year":"2021","unstructured":"Kopac T (2021) Protein corona, understanding the nanoparticle-protein interactions and future perspectives: A critical review. Int J Biol Macromol 169:290\u2013301. https:\/\/doi.org\/10.1016\/j.ijbiomac.2020.12.108","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"12068_CR90","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1038\/s41467-024-48838-5","volume":"15","author":"IV Zelepukin","year":"2024","unstructured":"Zelepukin IV, Shevchenko KG, Deyev SM (2024) Rediscovery of mononuclear phagocyte system blockade for nanoparticle drug delivery. Nat Commun 15(1):4366. https:\/\/doi.org\/10.1038\/s41467-024-48838-5","journal-title":"Nat Commun"},{"issue":"3","key":"12068_CR91","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s13346-020-00744-1","volume":"10","author":"MS Taha","year":"2020","unstructured":"Taha MS, Padmakumar S, Singh A, Amiji MM (2020) Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation. Drug Deliv Transl Res 10(3):766\u2013790. https:\/\/doi.org\/10.1007\/s13346-020-00744-1","journal-title":"Drug Deliv Transl Res"},{"key":"12068_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-026-04438-7","author":"R Xu","year":"2026","unstructured":"Xu R, Li N, Chen X, Zou M, Feng W, Zhou Z et al (2026) Lysosome-centered nanomedicine for cancer therapy: mechanisms, materials, and modalities. J Nanobiotechnol. https:\/\/doi.org\/10.1186\/s12951-026-04438-7","journal-title":"J Nanobiotechnol"},{"key":"12068_CR93","doi-asserted-by":"publisher","first-page":"1714460","DOI":"10.3389\/fphar.2025.1714460","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Huang P, Li C, Tu S, Yang H (2025) PLGA-based nanoparticles in colorectal cancer immunotherapy: current concepts and future perspectives. Front Pharmacol 16:1714460. https:\/\/doi.org\/10.3389\/fphar.2025.1714460","journal-title":"Front Pharmacol"},{"key":"12068_CR94","doi-asserted-by":"publisher","first-page":"1680053","DOI":"10.3389\/fimmu.2025.1680053","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Huang P, Li C, Tu S, Yang H (2025) Nanovaccines in gastrointestinal cancers. Front Immunol 16:1680053. https:\/\/doi.org\/10.3389\/fimmu.2025.1680053","journal-title":"Front Immunol"},{"issue":"10","key":"12068_CR95","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1080\/1061186x.2024.2393417","volume":"32","author":"S Heydari","year":"2024","unstructured":"Heydari S, Masoumi N, Esmaeeli E, Ayyoubzadeh SM, Ghorbani-Bidkorpeh F, Ahmadi M (2024) Artificial intelligence in nanotechnology for treatment of diseases. J Drug Target 32(10):1247\u20131266. https:\/\/doi.org\/10.1080\/1061186x.2024.2393417","journal-title":"J Drug Target"},{"key":"12068_CR96","doi-asserted-by":"publisher","first-page":"6253","DOI":"10.2147\/ijn.S459710","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, Deng T, Liu X, Fang X, Mo Y, Xie N et al (2024) Smart Nanoplatforms Responding to the Tumor Microenvironment for Precise Drug Delivery in Cancer Therapy. Int J Nanomed 19:6253\u20136277. https:\/\/doi.org\/10.2147\/ijn.S459710","journal-title":"Int J Nanomed"},{"key":"12068_CR97","doi-asserted-by":"publisher","first-page":"114773","DOI":"10.1016\/j.addr.2023.114773","volume":"196","author":"T Sun","year":"2023","unstructured":"Sun T, Jiang C (2023) Stimuli-responsive drug delivery systems triggered by intracellular or subcellular microenvironments. Adv Drug Deliv Rev 196:114773. https:\/\/doi.org\/10.1016\/j.addr.2023.114773","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"12068_CR98","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s11658-022-00348-2","volume":"27","author":"M Vaghari-Tabari","year":"2022","unstructured":"Vaghari-Tabari M, Hassanpour P, Sadeghsoltani F, Malakoti F, Alemi F, Qujeq D et al (2022) CRISPR\/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. Cell Mol Biol Lett 27(1):49. https:\/\/doi.org\/10.1186\/s11658-022-00348-2","journal-title":"Cell Mol Biol Lett"},{"issue":"15","key":"12068_CR99","doi-asserted-by":"publisher","first-page":"e2409202","DOI":"10.1002\/advs.202409202","volume":"12","author":"Y Guo","year":"2025","unstructured":"Guo Y, Luo S, Liu S, Yang C, Lv W, Liang Y et al (2025) Bimodal In Situ Analyzer for Circular RNA in Extracellular Vesicles Combined with Machine Learning for Accurate Gastric Cancer Detection. Adv Sci (Weinh) 12(15):e2409202. https:\/\/doi.org\/10.1002\/advs.202409202","journal-title":"Adv Sci (Weinh)"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12068-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12068-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12068-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:04:06Z","timestamp":1780437846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12068-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12068"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12068-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present article did not require institutional review board approval because we do not report human participant data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"872"}}